Incyte nabs priority review for bile duct cancer drug; Temasek shows interest in another Woodford darling — report
→ Incyte’s decision to stop co-funding baricitinib in favor of other pipeline opportunities is paying off, as the FDA grants priority review to pemigatinib in a type of previously treated, locally advanced or metastatic cholangiocarcinoma. Patients currently have “limited treatment options beyond first-line chemotherapy and often face a poor prognosis,” said Peter Langmuir, group vice president for targeted therapeutics. The drug inhibits fibroblast growth factor receptor, or FGFR, and has been shown to induce an overall response rate of 36% with a median duration of response of 7.5 months among patients with FGFR2 fusions or rearrangements. The PDUFA date is set for May 30, 2020.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.